2-(2,5-Dioxopyrrolidin-1-yl)sulfanylacetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(2,5-Dioxopyrrolidin-1-yl)sulfanylacetic acid
• 英文别名: 2-(2,5-dioxopyrrolidin-1-yl)sulfanylacetic acid
• 化学式: C₆H₇NO₄S
• 分子量: 189.19
• InChiKey: UWMVKAKBYCBBQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Conjugates of the B-subunit of Shiga toxin for anticancer therapies
  申请人：Institut Curie

  公开号：EP2740493A1

  公开（公告）日：2014-06-11

  Conjugates or pharmaceutical compositions comprising conjugates of the B-subunit of Shiga toxin that are useful for cancer therapies are disclosed. More specifically, the pharmaceutical compositions comprise STxB conjugated to at least one antimitotic agent such as auristatin or pharmaceutically acceptable salts thereof through a bifunctional linker. Processes to make the conjugates, as well as methods to treat cancers are also disclosed.

  披露了用于癌症治疗的B亚单位志贺毒素偶联物或药物组合物。更具体地说，药物组合物包括通过双功能连接剂将STxB偶联至少一种抗有丝分裂剂，如auriSTatin或药用可接受盐。还披露了制造偶联物的方法以及治疗癌症的方法。
• Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
  申请人：Institut Curie

  公开号：EP2740491A1

  公开（公告）日：2014-06-11

  Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least one T or a noncleavable linker; GNS is a gold nanostructure; S is a sulfhydryl group and x and y can vary from 1 to 8,000; and T is a molecule selected from the group of: contrast agents, cytotoxic agents, prodrugs and antigens and x and y can vary from 1 to 10,000. These multivalent conjugates can be used in therapy to treat cancer and in medical imaging. Methods to distinguish normal cells from abnormal cells and methods for treating cancer by photothermal therapy or photothermal therapy and cytotoxic therapy are also part of the present invention.

  包含以下公式的多价结合物：(STxB-连接剂A-S)x-GNS-(S-连接剂B-T)y，其中STxB是Shiga毒素的B亚单位；连接剂A是不可切割的连接剂；连接剂B是可切割的连接剂，用于释放至少一个T或不可切割的连接剂；GNS是金纳米结构；S是硫醇基团，x和y可以在1到8000之间变化；T是从对比剂、细胞毒性剂、前药和抗原组中选择的分子，x和y可以在1到10000之间变化。这些多价结合物可用于治疗癌症和医学成像。区分正常细胞和异常细胞的方法以及通过光热疗法或光热疗法和细胞毒疗法治疗癌症的方法也是本发明的一部分。
• [EN] CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR USE AS CONTRASTING AGENTS FOR IMAGING AND THERAPY<br/>[FR] CONJUGUÉS DE LA SOUS-UNITÉ B DE TOXINE DE SHIGA DESTINÉS À ÊTRE UTILISÉS COMME AGENTS DE CONTRASTE EN IMAGERIE ET EN THÉRAPIE
  申请人：INST CURIE

  公开号：WO2014086942A1

  公开（公告）日：2014-06-12

  Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least one T or a noncleavable linker; GNS is a gold nanostructure; S is a sulfhydryl group and x and y can vary from 1 to 8,000; and T is a molecule selected from the group of: contrast agents, cytotoxic agents, prodrugs and antigens and x and y can vary from 1 to 10,000. These multivalent conjugates can be used in therapy to treat cancer and in medical imaging. Methods to distinguish normal cells from abnormal cells and methods for treating cancer by photothermal therapy or photothermal therapy and cytotoxic therapy are also part of the present invention.

  包含以下公式的多价结合物：(STxB-连接剂A-S)x-GNS-(S-连接剂B-T)y，其中STxB是志贺毒素的B亚单位；连接剂A是不可切割的连接剂；连接剂B是可切割的连接剂，用于释放至少一个T或不可切割的连接剂；GNS是金纳米结构；S是硫醇基团，x和y的值可在1到8,000之间变化；T是从对比剂、细胞毒剂、前药和抗原组中选择的分子，x和y的值可在1到10,000之间变化。这些多价结合物可用于治疗癌症和医学成像。区分正常细胞和异常细胞的方法以及通过光热疗法或光热疗法和细胞毒疗法治疗癌症的方法也属于本发明的一部分。
• ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF
  申请人：REMEGEN, LTD

  公开号：EP3072907A1

  公开（公告）日：2016-09-28

  Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.

  本发明公开了一种抗 HER2 抗体以及该抗 HER2 抗体与小分子药物的共轭物。还公开了抗体及其共轭物在制备治疗肿瘤药物中的用途。
• ANTI-MESOTHELIN ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
  申请人：RemeGen, Ltd.

  公开号：EP3695852A1

  公开（公告）日：2020-08-19

  The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.

  本发明公开了一种靶向 MSLN 的抗体药物共轭物。本发明还公开了一种抗体药物共轭物（ADC）的制作方法。本发明进一步公开了一种新型 MSLN 抗体或其功能片段，包括工程化的重链和轻链。